LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced the pricing of an underwritten
public offering of 979,592 shares of its common stock at $122.50 per
share. The Company has granted the underwriters for the offering a
30-day option to purchase up to 146,938 additional shares of common
stock at the public offering price, less the underwriting discount. The
offering is expected to close on or about February 14, 2014.
BofA Merrill Lynch, Citigroup and Leerink Partners LLC are acting as
joint book-running managers for the offering. Cowen and Company, LLC and
UBS Securities LLC are acting as co-managers for the offering.
A registration statement on Form S-3 relating to these securities has
been filed with the Securities and Exchange Commission and declared
effective. The offering of these securities will be made only by means
of a written prospectus forming part of the effective registration
statement relating to these securities. Copies of the prospectus for
this offering may be obtained, when available, by contacting BofA
Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus
Department, email: dg.prospectus_requests@baml.com;
Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, phone (800) 831-9146; or Leerink Partners LLC, One
Federal Street, 37th Floor, Boston, MA 02110, Attn: Syndicate
Department, phone: (800) 808-7525.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical
company that acquires and develops innovative products for the treatment
of various forms of cancer. The Company focuses on in-licensing drug
candidates that are undergoing or have already completed initial
clinical testing for the treatment of cancer and then seeks to further
develop those drug candidates for commercial use. The Company is
initially focused on the development of PB272 (oral neratinib), a potent
irreversible tyrosine kinase inhibitor, for the treatment of patients
with HER2-positive metastatic breast cancer and patients with non-small
cell lung cancer, breast cancer and other solid tumors that have a HER2
mutation.
Contact:
Puma Biotechnology, Inc.
Mariann Ohanesian, +1 424-248-6500